Nuvation Bio Inc [NYSE: NUVB] plunged by -$0.29 during the normal trading session on while it closed the day at $2.09.
Nuvation Bio Inc stock has also loss -4.13% of its value over the past 7 days. However, NUVB stock has declined by -13.28% in the 3 months of the year. Over the past six months meanwhile, it has lost -5.43% and lost -21.43% year-on date.
The market cap for NUVB stock reached $709.91 million, with 336.84 million shares outstanding and 226.88 million shares in the current float. Compared to the average trading volume of 2.82M shares, NUVB reached a trading volume of 3852811 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Nuvation Bio Inc [NUVB]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NUVB shares is $7.43 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NUVB stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Citizens JMP have made an estimate for Nuvation Bio Inc shares, keeping their opinion on the stock as Mkt Outperform, with their previous recommendation back on April 23, 2025. While these analysts kept the previous recommendation, Jefferies raised their target price from $1.40 to $10. The new note on the price target was released on March 27, 2024, representing the official price target for Nuvation Bio Inc stock. Previously, the target price had yet another raise to $5, while BTIG Research analysts kept a Buy rating on NUVB stock. On January 06, 2023, analysts decreased their price target for NUVB shares from 5 to 2.
The Average True Range (ATR) for Nuvation Bio Inc is set at 0.17, with the Price to Sales ratio for NUVB stock in the period of the last 12 months amounting to 90.20. The Price to Book ratio for the last quarter was 1.52, with the Price to Cash per share for the same quarter was set at 1.48.
NUVB stock trade performance evaluation
Nuvation Bio Inc [NUVB] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -4.13. With this latest performance, NUVB shares gained by 25.90% in over the last four-week period, additionally sinking by -5.43% over the last 6 months – not to mention a drop of -36.09% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NUVB stock in for the last two-week period is set at 50.22, with the RSI for the last a single of trading hit 46.96, and the three-weeks RSI is set at 50.49 for Nuvation Bio Inc [NUVB]. The present Moving Average for the last 50 days of trading for this stock 1.98, while it was recorded at 2.29 for the last single week of trading, and 2.52 for the last 200 days.
Nuvation Bio Inc [NUVB]: An insightful look at the core fundamentals
Nuvation Bio Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 9.04 and a Current Ratio set at 9.04.
Earnings per share (EPS) analysis for Nuvation Bio Inc [NUVB] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NUVB. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Nuvation Bio Inc go to 37.71%.
Nuvation Bio Inc [NUVB]: Institutional Ownership
The top three institutional holders of NUVB stocks are: FMR LLC with ownership of 28.82 million shares, which is approximately 11.7767%. ECOR1 CAPITAL, LLC, holding 19.21 million shares of the stock with an approximate value of $$56.09 million in NUVB stocks shares; and ECOR1 CAPITAL, LLC, currently with $$47.41 million in NUVB stock with ownership which is approximately 6.6343%.
